OTR3® is a biotechnology company founded by Professors Denis Barritault and Jean-Pierre Caruelle† from the University of Paris-East Créteil in 2000, laureates of the French national competition for the creation of the best innovative company. Known for their pioneering work on growth factors – the discovery of FGF, HARP/PTN – they invented the RGTA® Technology (ReGeneraTing Agents), a new therapeutic class in regenerative medicine.

The RGTA® Technology is patent protected worldwide.

OTR3® has currently one CE marked medical device CACIPLIQ20® on the market.

OTR3® is the recipient of a H2020 SME Instrument Phase 2 funding to develop a new therapeutic product for the treatment of ischemic stroke.